Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Verified

Overview

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.

SparkCures ID 1092
Trial Phase Phase 2
Enrollment 30 Patients
Treatments
Tags
Trial Sponsors
  • Cartesian Therapeutics
NCT Identifier

NCT04436029
ACCEPTING

This trial is currently open and accepting patients.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Patients must be 18 years of age or older at the time of enrollment
  • High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).

Exclusion Criteria:

  • Patients who are pregnant or lactating.
  • Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.
🤔 Am I Eligible?

Understanding this criteria can be difficult - call us today.

(888) 828-2206 Create My Account

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

John Theurer Cancer Center Hackensack Meridian Health
John Theurer Cancer Center Hackensack Meridian Health

Hackensack, NJ

Medical College of Wisconsin Froedtert Hospital
Medical College of Wisconsin Froedtert Hospital

Milwaukee, WI

American Oncology Partners of Maryland (Bethesda) The Center for Cancer & Blood Disorders - Bethesda
American Oncology Partners of Maryland (Bethesda) The Center for Cancer & Blood Disorders - Bethesda

Bethesda, MD

University of Oklahoma Health Sciences Center
University of Oklahoma Health Sciences Center

Oklahoma City, OK

Maryland
American Oncology Partners of Maryland (Bethesda) The Center for Cancer & Blood Disorders - Bethesda
American Oncology Partners of Maryland (Bethesda) The Center for Cancer & Blood Disorders - Bethesda

Bethesda, MD

  • Recruiting
New Jersey
John Theurer Cancer Center Hackensack Meridian Health
John Theurer Cancer Center Hackensack Meridian Health

Hackensack, NJ

  • Recruiting
Oklahoma
University of Oklahoma Health Sciences Center
University of Oklahoma Health Sciences Center

Oklahoma City, OK

  • Recruiting
Wisconsin
Medical College of Wisconsin Froedtert Hospital
Medical College of Wisconsin Froedtert Hospital

Milwaukee, WI

  • Recruiting

Resources

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Cartesian Therapeutics to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors